a Department of Cancer Medicine, Gustave Roussy Cancer Center , University of Paris Saclay , Villejuif , France.
b INSERM U981 Gustave Roussy Cancer Center , University of Paris Sud , Villejuif , France.
Expert Rev Anticancer Ther. 2019 Jun;19(6):437-446. doi: 10.1080/14737140.2019.1607302. Epub 2019 May 16.
: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings. : We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research. : All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited.
聚二磷酸腺苷核糖聚合酶（PARP）抑制剂在卵巢癌中的应用前景正在迅速发展，并变得越来越复杂。卵巢癌为 DNA 修复作为靶点提供了概念验证，从而引领了治疗学的创新。目前已有三种不同的 PARP 抑制剂在美国和欧洲获得了不同适应证的批准。在每种 PARP 抑制剂的许可适应证中，组织学、突变类型（种系和/或体细胞）、先前化疗线数以及适应证是在治疗还是维持设置方面，都存在细微但至关重要的差异。我们回顾了 PARP 抑制剂芦卡帕尼在卵巢癌中的最新临床数据，提供了卵巢癌中 PARP 抑制作用不断发展的最新情况，并总结了正在进行和未来的研究方向。所有符合条件的患者都应考虑使用 PARP 抑制剂。SOLO1 试验结果表明，PARP 抑制剂在一线维持治疗中具有前所未有的获益。正在等待评估 PARP 抑制剂作为一线维持治疗（无论 BRCA 状态如何）和评估联合治疗策略的试验结果。
